A microRNA signature associated with early recurrence in breast cancer

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Pérez Rivas, Luis G ^a   Jerez, José M ^b   Carmona, Rosario ^b   Luque, Vanessade ^a   Vicioso, Luis ^a   Claros, M Gonzalo ^b   Viguera, Enrique ^b   Pajares, Bella ^a   Sańchez, Alfonso ^a   Ribelles, Nuria ^a   Alba, Emilio ^a   Lozano, José ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 10A; MICRORNA 149; MICRORNA 20B; MICRORNA 30A 3P; MICRORNA 342 5P; UNCLASSIFIED DRUG;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE INTERVAL; DOWN REGULATION; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE ONTOLOGY; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PREDICTIVE VALUE; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE ONTOLOGY; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ROC CURVE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898441297     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091884     Document Type: Article

References (107)

1. Fisher ER, Palekar AS, Gregorio RM, Redmond C, Fisher B (1978) Pathological findings from the national surgical adjuvant breast project (Protocol No. 4). IV. Significance of tumor necrosis. Hum Pathol 9: 523-530. (Pubitemid 9030683)
2. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874. (Pubitemid 32878711)
5. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20: 628-635.
6. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904.
7. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359: 2814-2823.
8. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746. (Pubitemid 26329660)
9. Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G (1996) Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat 41: 177-185. (Pubitemid 26360147)
10. Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG (2005) Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat 89: 173-178. (Pubitemid 40249051)
11. Demicheli R, Retsky MW, Hrushesky WJ, Baum M (2007) Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 4: 699-710. (Pubitemid 350187005)
12. Demicheli R, Hrushesky WJ, Retsky MW, Bonadonna G, Valagussa P (2007) Comment to "Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and intact primary tumor" by G V Babiera, R Rao, L Feng, F Meric-Bernstam, H M Kuerer, S E Singletary, K K Hunt, M I Ross, K M Gwyn, B W Feig, F C Ames, G N Horthobagyi. Ann Surg Oncol 2006;13:776-782. Ann Surg Oncol 14: 1519-1520. (Pubitemid 46536822)
13. Demicheli R, Retsky MW, Hrushesky WJ, Baum M, Gukas ID (2008) The effects of surgery on tumor growth: a century of investigations. Ann Oncol 19: 1821-1828.
14. Demicheli R, Valagussa P, Bonadonna G (2001) Does surgery modify growth kinetics of breast cancer micrometastases? Br J Cancer 85: 490-492. (Pubitemid 32808269)
15. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78: 105-118. (Pubitemid 36223023)
16. Demicheli R, Biganzoli E, Ardoino I, Boracchi P, Coradini D, et al. (2010) Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 101: 826-830.
17. Perez-Rivas LG, Jerez JM, Fernandez-De Sousa CE, de Luque V, Quero C, et al. (2012) Serum protein levels following surgery in breast cancer patients: a protein microarray approach. Int J Oncol 41: 2200-2206.
18. Carlsson A, Wingren C, Kristensson M, Rose C, Ferno M, et al. (2011) Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases. Proc Natl Acad Sci U S A 108: 14252-14257.
19. Pietrowska M, Polanska J, Marczak L, Behrendt K, Nowicka E, et al. (2010) Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer. J Transl Med 8: 66.
20. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11: 5678-5685. (Pubitemid 41170290)
21. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, et al. (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16: 5222-5232.
22. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, et al. (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750.
23. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, et al. (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14: 1368-1376. (Pubitemid 351413917)
24. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, et al. (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28: 3271-3277.
25. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27: 1160-1167.
26. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, et al. (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28: 1684-1691.
27. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
28. Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013) A new genome-driven integrated classification of breast cancer and its implications. EMBO J 32: 617-628.
29. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
30. Djuranovic S, Nahvi A, Green R (2011) A parsimonious model for gene regulation by miRNAs. Science 331: 550-553.
31. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U (2004) Nuclear export of microRNA precursors. Science 303: 95-98. (Pubitemid 38055779)
32. Brodersen P, Voinnet O (2009) Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 10: 141-148.
33. Carthew RW, Sontheimer EJ (2009) Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655.
34. Huntzinger E, Izaurralde E (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12: 99-110.
35. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36: D154-158. (Pubitemid 351149713)
36. Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714.
37. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103: 2257-2261. (Pubitemid 43271657)
38. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
39. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285: 116-126.
40. Grammatikakis I, Gorospe M, Abdelmohsen K (2013) Modulation of Cancer Traits by Tumor Suppressor microRNAs. Int J Mol Sci 14: 1822-1842.
41. White NM, Fatoohi E, Metias M, Jung K, Stephan C, et al. (2011) Metastamirs: a stepping stone towards improved cancer management. Nat Rev Clin Oncol 8: 75-84.
42. Cho WC (2007) OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6: 60.
43. Lee YS, Dutta A (2009) MicroRNAs in cancer. Annu Rev Pathol 4: 199-227.
44. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, et al. (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105: 13021-13026.
45. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838. (Pubitemid 40839735)
46. Volinia S, Croce CM (2013) Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A 110: 7413-7417.
47. Pritchard CC, Cheng HH, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13: 358-369.
48. Bartels CL, Tsongalis GJ (2009) MicroRNAs: novel biomarkers for human cancer. Clin Chem 55: 623-631.
49. Shi M, Liu D, Duan H, Shen B, Guo N (2010) Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev 29: 785-799.
50. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374. (Pubitemid 39100473)
51. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145. (Pubitemid 350003059)
52. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
53. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193. (Pubitemid 36181903)
54. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
55. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
56. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
57. Breitling R, Armengaud P, Amtmann A, Herzyk P (2004) Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 573: 83-92. (Pubitemid 39141040)
58. Lumley T (2007) The survival package. R help guide.
59. Cox DR, Oakes D (1984) Analysis of survival data. London; New York: Chapman and Hall. viii, 201 p. p.
60. Sakamoto Y, Ishiguro M, Kitagawa G (1986) Akaike information criterion statistics. Tokyo Dordrecht; Boston Hingham, MA: KTK Scientific Publishers; D. Reidel; Sold and distributed in the U.S.A. and Canada by Kluwer Academic Publishers. xix, 290 p. p.
61. Molinaro AM, Simon R, Pfeiffer RM (2005) Prediction error estimation: a comparison of resampling methods. Bioinformatics 21: 3301-3307. (Pubitemid 41418445)
62. Efron B, Tibshirani R (1993) An introduction to the bootstrap. New York: Chapman & Hall. xvi, 436 p. p.
63. Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4: 309-314.
64. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, et al. (2011) miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 39: D163-169.
65. Xiao F, Zuo Z, Cai G, Kang S, Gao X, et al. (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37: D105-110.
66. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)
67. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, et al. (2009) ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25: 1091-1093.
68. Bindea G, Galon J, Mlecnik B (2013) CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 29: 661-663.
69. Kutmon M, Kelder T, Mandaviya P, Evelo CT, Coort SL (2013) CyTargetLinker: A Cytoscape App to Integrate Regulatory Interactions in Network Analysis. PLoS One 8: e82160.
70. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, et al. (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8: R214.
71. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, et al. (2012) Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 109: 2802-2807.
72. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, et al. (2013) The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497: 378-382.
73. Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, et al. (2009) MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res 11: R27.
74. Van der Auwera I, Limame R, van Dam P, Vermeulen PB, Dirix LY, et al. (2010) Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 103: 532-541.
75. Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Quintanar-Jurado V, Maffuz-Aziz A, et al. (2012) Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One 7: e31904.
76. Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, et al. (2010) Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod Pathol 23: 1567-1576.
77. Liu H, Brannon AR, Reddy AR, Alexe G, Seiler MW, et al. (2010) Identifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma. BMC Syst Biol 4: 51.
78. Takeshita H, Shiozaki A, Bai XH, Iitaka D, Kim H, et al. (2013) XB130, a new adaptor protein, regulates expression of tumor suppressive microRNAs in cancer cells. PLoS One 8: e59057.
79. Tu HF, Liu CJ, Chang CL, Wang PW, Kao SY, et al. (2012) The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS One 7: e51606.
80. Wang F, Ma YL, Zhang P, Shen TY, Shi CZ, et al. (2013) SP1 mediates the link between methylation of the tumour suppressor miR-149 and outcome in colorectal cancer. J Pathol 229: 12-24.
81. Wang Y, Zheng X, Zhang Z, Zhou J, Zhao G, et al. (2012) MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS One 7: e41693.
82. Yu F, Deng H, Yao H, Liu Q, Su F, et al. (2010) Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 29: 4194-4204.
83. Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, et al. (2012) MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 130: 2044-2053.
84. Caruso S, Bazan V, Rolfo C, Insalaco L, Fanale D, et al. (2012) MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis 1: e32.
85. Lee H, Park CS, Deftereos G, Morihara J, Stern JE, et al. (2012) MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol 10: 174.
86. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360.
87. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, et al. (2011) MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 127: 43-51.
88. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, et al. (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68: 6162-6170.
89. Dylla L, Jedlicka P (2013) Growth-promoting role of the miR-106a∼363 cluster in Ewing sarcoma. PLoS One 8: e63032.
90. Iqbal J, Shen Y, Liu Y, Fu K, Jaffe ES, et al. (2012) Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 119: 4939-4948.
91. Landais S, Landry S, Legault P, Rassart E (2007) Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res 67: 5699-5707. (Pubitemid 46985002)
92. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, et al. (2009) The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 106: 15732-15737.
93. Rothe F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, et al. (2011) Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. PLoS One 6: e20980.
94. Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, et al. (2010) miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 224: 242-249.
95. Lei Z, Li B, Yang Z, Fang H, Zhang GM, et al. (2009) Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 4: e7629.
96. Lund AH (2010) miR-10 in development and cancer. Cell Death Differ 17: 209-214.
97. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF (2010) MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A 107: 13450-13455.
98. Huang H, Xie C, Sun X, Ritchie RP, Zhang J, et al. (2010) miR-10a contributes to retinoid acid-induced smooth muscle cell differentiation. J Biol Chem 285: 9383-9389.
99. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, et al. (2010) Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127: 1785-1794.
100. Segura MF, Belitskaya-Levy I, Rose AE, Zakrzewski J, Gaziel A, et al. (2010) Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res 16: 1577-1586.
101. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, et al. (2013) The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 127: 1609-1619.
102. Naumov GN, Akslen LA, Folkman J (2006) Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5: 1779-1787. (Pubitemid 44435320)
103. Aguirre-Ghiso JA (2007) Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 7: 834-846.
104. McCarthy N (2013) A perivascular niche can promote dormancy. Nat Rev Cancer 13: 441.
105. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, et al. (2008) hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348. (Pubitemid 351413913)
106. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, et al. (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 109: 3024-3029.
107. Quackenbush (2002) Microarray data normalization and transformation. Nat Genet 32 Suppl: 496-501.